CN101773529B - 一种治疗心脑血管疾病的中药组合物及其制剂 - Google Patents
一种治疗心脑血管疾病的中药组合物及其制剂 Download PDFInfo
- Publication number
- CN101773529B CN101773529B CN2010101275484A CN201010127548A CN101773529B CN 101773529 B CN101773529 B CN 101773529B CN 2010101275484 A CN2010101275484 A CN 2010101275484A CN 201010127548 A CN201010127548 A CN 201010127548A CN 101773529 B CN101773529 B CN 101773529B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- folium ginkgo
- chinese medicine
- extraction
- eluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 28
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 28
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 45
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000007901 soft capsule Substances 0.000 claims abstract description 17
- 239000006187 pill Substances 0.000 claims abstract description 14
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 184
- 241000218628 Ginkgo Species 0.000 claims description 62
- 235000011201 Ginkgo Nutrition 0.000 claims description 62
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 62
- 239000000284 extract Substances 0.000 claims description 54
- 238000000605 extraction Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 239000003480 eluent Substances 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 23
- 239000004952 Polyamide Substances 0.000 claims description 15
- 230000006837 decompression Effects 0.000 claims description 15
- 229920002647 polyamide Polymers 0.000 claims description 15
- 238000004064 recycling Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000019634 flavors Nutrition 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
- 229960002216 methylparaben Drugs 0.000 claims description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000010410 layer Substances 0.000 claims description 5
- 239000012044 organic layer Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- IKHGABNOFYINCR-UHFFFAOYSA-N 5-methoxybenzene-1,2,3,4-tetrol Chemical compound COC1=CC(O)=C(O)C(O)=C1O IKHGABNOFYINCR-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000008118 PEG 6000 Substances 0.000 claims description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 4
- 229940087511 calcium disodium versenate Drugs 0.000 claims description 4
- 238000005189 flocculation Methods 0.000 claims description 4
- 230000016615 flocculation Effects 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 4
- 229960005055 sodium ascorbate Drugs 0.000 claims description 4
- 235000010265 sodium sulphite Nutrition 0.000 claims description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 241001411320 Eriogonum inflatum Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000011265 semifinished product Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 208000035126 Facies Diseases 0.000 claims 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 18
- 239000007924 injection Substances 0.000 abstract description 18
- 238000011160 research Methods 0.000 abstract description 9
- 239000007788 liquid Substances 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 208000031225 myocardial ischemia Diseases 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 239000012567 medical material Substances 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- -1 flavones chemical compound Chemical class 0.000 description 5
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000010212 ginaton Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
超声功率、频塞 | 干膏得率% | 总黄酮醇苷量(mg/g干叶) | 萜类内酯量(mg/g干叶) |
250W/20KHZ | 18.1 | 7.62 | 2.29 |
250W/25KHZ | 18.5 | 7.65 | 2.33 |
250W/40KHZ | 18.7 | 6.64 | 2.31 |
250W/50KHZ | 18.6 | 7.66 | 2.34 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101275484A CN101773529B (zh) | 2010-03-19 | 2010-03-19 | 一种治疗心脑血管疾病的中药组合物及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101275484A CN101773529B (zh) | 2010-03-19 | 2010-03-19 | 一种治疗心脑血管疾病的中药组合物及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101773529A CN101773529A (zh) | 2010-07-14 |
CN101773529B true CN101773529B (zh) | 2012-08-08 |
Family
ID=42510204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101275484A Active CN101773529B (zh) | 2010-03-19 | 2010-03-19 | 一种治疗心脑血管疾病的中药组合物及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101773529B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105010409A (zh) * | 2015-07-09 | 2015-11-04 | 潍坊友容实业有限公司 | 一种含有银杏叶提取物的除草剂及其在盐碱地荞麦种植中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1480172A (zh) * | 2002-09-02 | 2004-03-10 | 北京大学安康药物研究院 | 一种复方葛根素制剂 |
CN1586548A (zh) * | 2004-07-16 | 2005-03-02 | 北京国仁堂医药科技发展有限公司 | 一种银杏叶提取物及其提取方法 |
CN101152222A (zh) * | 2006-09-28 | 2008-04-02 | 浙江大学宁波理工学院 | 一种超声波辅助提取银杏叶中总黄酮的方法 |
-
2010
- 2010-03-19 CN CN2010101275484A patent/CN101773529B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1480172A (zh) * | 2002-09-02 | 2004-03-10 | 北京大学安康药物研究院 | 一种复方葛根素制剂 |
CN1586548A (zh) * | 2004-07-16 | 2005-03-02 | 北京国仁堂医药科技发展有限公司 | 一种银杏叶提取物及其提取方法 |
CN101152222A (zh) * | 2006-09-28 | 2008-04-02 | 浙江大学宁波理工学院 | 一种超声波辅助提取银杏叶中总黄酮的方法 |
Non-Patent Citations (1)
Title |
---|
国家药典委员会.葛根素.《中华人民共和国药典 2005版 二部》.2005,第688页右栏正文第1段. * |
Also Published As
Publication number | Publication date |
---|---|
CN101773529A (zh) | 2010-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1257724C (zh) | 一种预防和治疗糖尿病的组合物 | |
CN108042627B (zh) | 一种治疗高尿酸血症的组合物及其制备方法和用途 | |
CN102218049B (zh) | 抗衰老的药物或保健食品组合物及用途 | |
CN1840166A (zh) | 温胆汤现代中药口服制剂及其生产方法 | |
CN101239081A (zh) | 一种用于癌症治疗的组合物及其制备方法 | |
CN102697982B (zh) | 一种具有辅助降血脂功能的组合物及其制备方法 | |
CN101099753A (zh) | 救必应总皂苷的制备方法及应用 | |
CN101773529B (zh) | 一种治疗心脑血管疾病的中药组合物及其制剂 | |
CN102319289A (zh) | 肉桂多酚等组成的降血糖中药组合物及其制备方法 | |
CN102614280B (zh) | 一种具有降低血脂功效的中药组合物及其制备方法和应用 | |
CN101134057B (zh) | 含紫杉醇的天然植物提取物的复方药物及其抗癌应用 | |
CN102488721B (zh) | 一种银杏叶提取物的制备方法及其制剂 | |
CN107854656B (zh) | 一种降脂中药组合物及其制备方法和用途 | |
CN100342861C (zh) | 一种红曲提取物及其制剂 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN104997018A (zh) | 一种红豆杉酵素保健品及其制备方法和应用 | |
CN102028834B (zh) | 一种复方龙血竭制剂及其制备方法 | |
CN104804056A (zh) | 楮头红提取物及其应用 | |
CN101721456A (zh) | 一种抗动脉粥样硬化治疗心脑血管疾病的中药及其磷脂复合物制剂的制备方法 | |
CN101904891B (zh) | 一种银杏叶丸及其制备方法 | |
CN101099754A (zh) | 具栖冬青苷的制备方法及应用 | |
CN101049435A (zh) | 一种预防中、老年人脑痴呆营养品的制造方法 | |
CN101274011A (zh) | 核桃壳提取物的制备及其在强心和心脑血管领域药物制剂的应用 | |
CN103520235A (zh) | 一种具有降脂功能的植物组合物及其制备方法与应用 | |
CN102614372A (zh) | 一种抗疲劳的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201229 Address after: Room 402, gate 2, building 10, Panjiayuan, Chaoyang District, Beijing 100021 Patentee after: Xu Xinwen Address before: 102211 Beijing city Changping District town of Xiaotangshan elegant manor 3 Building 1 unit 401 room Patentee before: Zhuang Hongbo |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210303 Address after: Room 402, gate 2, building 10, Panjiayuan, Chaoyang District, Beijing 100021 Patentee after: Xu Xinwen Patentee after: Xu Boda Address before: Room 402, gate 2, building 10, Panjiayuan, Chaoyang District, Beijing 100021 Patentee before: Xu Xinwen |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210511 Address after: 100044 room 917, building 2, yard 66, Jiaoda East Road, Haidian District, Beijing Patentee after: BEIJING GUORENTANG PHARMACEUTICAL SCIENCE AND TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: Room 402, gate 2, building 10, Panjiayuan, Chaoyang District, Beijing 100021 Patentee before: Xu Xinwen Patentee before: Xu Boda |